<DOC>
	<DOCNO>NCT02739373</DOCNO>
	<brief_summary>The main purpose study measure amount study drug ( BMS-986189 ) blood urine see BMS-986189 safe well-tolerated healthy people single dose .</brief_summary>
	<brief_title>Pharmacokinetics , Safety , Tolerability Pharmacodynamics BMS-986189 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Healthy , males female , 18 55 year age , inclusive Body Mass Index ( BMI ) 18.0 30.0 kg/m2 , inclusive Women childbearing potential ( WOCBP ) must negative serum pregnancy test ( performed female ; minimum sensitivity 25 IU/L equivalent unit human chorionic gonadotropin ) within 24 hour prior start study drug Any significant acute chronic medical illness History diabetes mellitus , severe hypertriglyceridemia , acute chronic pancreatitis , pancreatic exocrine disorder History autoimmune disease Any known skin condition would affect subcutaneous dose Positive blood screen hepatitis C antibody ( HCV Ab ) , hepatitis B surface antigen ( HBsAg ) , HIV 1 HIV 2 antibody Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>